Results 1 – 10 of 46 for constipation (0.02 seconds)

MOVENTIG® approved in the European Union for opioid-induced constipation

MOVENTIG® approved in the European Union for opioid-induced constipation

MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation

MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation

AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes to Address Opioid-Induced Constipation

AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes to Address Opioid-Induced Constipation

AstraZeneca initiates phase III clinical programme evaluating NKTR-118 for treatment of opioid-induced constipation

AstraZeneca initiates phase III clinical programme evaluating NKTR-118 for treatment of opioid-induced constipation

AstraZeneca announces results from long-term safety trial of naloxegol in patients with opioid-induced constipation

AstraZeneca announces results from long-term safety trial of naloxegol in patients with opioid-induced constipation

Marketing Authorisation Application for naloxegol accepted by European Medicines Agency

specifically designed for the treatment of opioid-induced constipation (OIC) for adult patients 18 years and older, including patients with inadequate ...

FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain

FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain

Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation

Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation

AstraZeneca announces top-line phase III results from naloxegol pivotal trials in patients with opioid-induced constipation

AstraZeneca announces top-line phase III results from naloxegol pivotal trials in patients with opioid-induced constipation

US FDA Advisory Committee recommends no cardiovascular outcomes trial for peripherally-acting mu-opioid receptor antagonist (PAMORA) class including MOVANTIK

oxalate), an investigational treatment for opioid-induced constipation (OIC) for patients with chronic non-cancer pain. Following a clarification of ...

Previous 1 2 3 4 5 6 Next